Financings in Brief: Norian
This article was originally published in The Gray Sheet
Executive SummaryNorian: Cupertino, California-based developer of the Norian Skeletal Repair System files registration statement with SEC for an initial public offering of 3 mil. shares, expected to be priced between $12 and $14 each. Underwriters Alex. Brown and Robertson, Stephens have an over-allotment option to buy up to 450,000 additional shares. Norian's SRS system incorporates an "injectable, moldable and biocompatible cancellous bone fixation and replacement material" for fracture treatment...
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.